Cytokine-induced killer cell

Cytokine-induced killer cells or CIK cells are a group of immune effector cells featuring a mixed T- and natural killer (NK) cell-like phenotype. They are generated by ex vivo incubation of human peripheral blood mononuclear cells (PBMC) or cord blood mononuclear cells with interferon-gamma (IFN-γ), anti-CD3 antibody , recombinant human interleukin (IL-) 1 and recombinant human interleukin (IL)-2.

Typically, immune cells detect major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. However, CIK cells have the ability to recognize infected or even malignant cells in the absence of antibodies and MHC, allowing for a fast and unbiased immune reaction. This is of particular importance as harmful cells that are missing MHC markers cannot be tracked and attacked by other immune cells, such as T-lymphocytes.[1][2][3] As a special feature, terminally differentiated CD3+CD56+ CIK cells possess the capacity for both MHC-restricted and MHC-unrestricted anti-tumor cytotoxicity. These properties, inter alia, rendered CIK cells attractive as a potential therapy for cancer and viral infections.[4]

Nomenclature

They were given the name “cytokine-induced killer” because cultivation with certain cytokines is mandatory for the maturation into terminally differentiated CIK cells. Several sources also call them natural killer cell-like T cells due to their close relationship to NK cells. Others propose to classify CIK cells as subset of NKT cells.[5]

Mechanism

It has been shown that lymphocytes, when exposed to interferon-gamma, anti-CD3 antibody, interleukin-1 and interleukin 2, are capable of lysing fresh, non-cultured cancer cells, both primary and metastatic. CIK cells respond to these lymphokines, particularly IL-2, by lysing tumor cells that were already known to be resistant to NK cell or LAK cell activity.

Peripheral blood mononuclear cells or cord blood mononuclear cells are extracted from either peripheral blood or cord blood, e.g. by simple blood draw. Extracted cells are ex-vivo exposed to interferon-gamma, anti-CD3 antibody, interleukin-1 and interleukin-2 in a time-sensitive schedule. These cytokines strongly stimulate the proliferation and maturation into CIK cells.[1][2][4][6] After completed maturation CIK cells are transfused to the donor in autologous settings or to different recipients in allogeneic settings.

Function

The mechanism of CIK cells is distinctive from that of natural killer cells or LAK cells because they can lyse cells that NK cells and LAK cells cannot.

CIK cells have, as a key feature, a double T-cell and NK cell-like phenotype. This unique combination of T-cell and NK-cell capabilities exerts a potent and widely MHC-unrestricted anti-tumor cytotoxicity against a broad range of cancer cells.[2][4] Up to now the exact mechanisms of tumor recognition and targeted cytotoxicity of CIK cells is not fully understood. Besides recognition via TCR/CD3, NK-cell-like tumor recognition is mediated by cell-cell contact-dependent NKG2D, DNAM-1 and NKp30. These receptors and surface markers confer the capability of acting against cells that do not display the major histocompatibility complex, as has been shown by the ability to cause lysis in non-immunogenic, allogeneic and syngeneic tumors. Particularly solid and hematologic tumor cells tend to overexpress NKG2D ligands, making them a sought target of CIK cell-mediated cytolysis. Recognition is specific to tumor and virus infected cells as CIK cells do not display activity against healthy cells.[1][2][3][4]

Immunomodulatory Tregs were shown to inhibit CIK cell function.[7]

Cancer Treatment

CIK cells, along with the administration of IL-2 have been experimentally used to treat cancer in mice and humans with low toxicity.

Clinical trials

In a large number of phase I and phase II studies, autologous and allogeneic CIK cells displayed a high cytotoxic potential against a broad range of varying tumor entities, whereas side effects were only minor. In many cases, CIK cell treatment led to complete remissions of tumor burden, prolonged survival durations and improved quality of life, even in advanced disease stages. Currently, the utilization of CIK cell treatment is restricted to clinical studies, but this therapeutic approach might also benefit patients as first-line treatment modality in the future.[8][9]

International registry on CIK cells (IRCC)

The international registry on CIK cells (IRCC) was founded in 2011 as an independent organization, dedicated to collect data about clinical trials utilizing CIK cells and subsequent analysis to determine the latest state of clinical CIK cell research. A particular focus is thereby the evaluation of CIK cell efficacy in clinical trials and side effects.[8][9]

Future trends

In studies, researchers succeeded in the transfection of cells ex-vivo with cytokine-genes, e.g. IL-2. Gene-modified CIK cells showed an increased proliferation rate and enhanced toxicity.[10] Gene-transfected CIK cells were first applied in 1999 for the treatment of ten patients in metastatic state of disease.[11]

Evidence is growing that the interaction with dendritic cells (DC) or rather vaccinated DCs further improves the anti-tumor efficacy of CIK cells and joint cultivation additionally reduces the number of Tregs within the CIK cell culture, resulting in enhanced expansion and frequency of CD3+CD56+ cells in the amplified cell population.[12][13]

In-vitro studies revealed that CIK cells, redirected by chimeric antigen receptors with an antibody-defined specificity for different tumor antigens, showed an improved selectivity and activation in targeting antigen-presenting tumor cells.[14][15]

In-vitro and in-vivo activity of CIK cells in conjunction with bispecific antibodies, cross-linking cytotoxic effector cells with malignant targets, was enhanced compared with CIK cells alone.[16][17]

History

CIK cells were first described by Ingo G.H. Schmidt-Wolf in 1991,[1] who also performed the first clinical trial with CIK cells in the treatment of cancer patients in 1999.[11]

References

  1. 1 2 3 4 Schmidt-Wolf, IG; Negrin, RS; Kiem, HP; Blume, KG; Weissman, IL (1 July 1991). "Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.". The Journal of Experimental Medicine 174 (1): 139–49. doi:10.1084/jem.174.1.139. PMID 1711560.
  2. 1 2 3 4 Schmidt-Wolf, IG; Lefterova, P; Mehta, BA; Fernandez, LP; Huhn, D; Blume, KG; Weissman, IL; Negrin, RS (December 1993). "Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.". Experimental hematology 21 (13): 1673–9. PMID 7694868.
  3. 1 2 Lu, PH; Negrin, RS (15 August 1994). "A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.". Journal of immunology (Baltimore, Md. : 1950) 153 (4): 1687–96. PMID 7519209.
  4. 1 2 3 4 Pievani, A; Borleri, G; Pende, D; Moretta, L; Rambaldi, A; Golay, J; Introna, M (22 September 2011). "Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.". Blood 118 (12): 3301–10. doi:10.1182/blood-2011-02-336321. PMID 21821703.
  5. ↑ Godfrey, DI; MacDonald, HR; Kronenberg, M; Smyth, MJ; Van Kaer, L (March 2004). "NKT cells: what's in a name?". Nature reviews. Immunology 4 (3): 231–7. doi:10.1038/nri1309. PMID 15039760.
  6. ↑ Introna, M; Pievani, A; Borleri, G; Capelli, C; Algarotti, A; Micò, C; Grassi, A; Oldani, E; Golay, J; Rambaldi, A (November 2010). "Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.". Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 16 (11): 1603–7. doi:10.1016/j.bbmt.2010.05.015. PMID 20685246.
  7. ↑ Li, H; Yu, JP; Cao, S; Wei, F; Zhang, P; An, XM; Huang, ZT; Ren, XB (May 2007). "CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients.". Journal of clinical immunology 27 (3): 317–26. doi:10.1007/s10875-007-9076-0. PMID 17468835.
  8. 1 2 Schmeel, LC; Schmeel, FC; Coch, C; Schmidt-Wolf, IG (8 November 2014). "Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).". Journal of cancer research and clinical oncology 141: 839–49. doi:10.1007/s00432-014-1864-3. PMID 25381063.
  9. 1 2 Hontscha, C; Borck, Y; Zhou, H; Messmer, D; Schmidt-Wolf, IG (February 2011). "Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).". Journal of cancer research and clinical oncology 137 (2): 305–10. doi:10.1007/s00432-010-0887-7. PMID 20407789.
  10. ↑ Jäkel, Clara E; Schmidt-Wolf, Ingo GH (July 2014). "An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells". Expert Opinion on Biological Therapy 14 (7): 905–916. doi:10.1517/14712598.2014.900537.
  11. 1 2 Schmidt-Wolf, IG; Finke, S; Trojaneck, B; Denkena, A; Lefterova, P; Schwella, N; Heuft, HG; Prange, G; Korte, M; Takeya, M; Dorbic, T; Neubauer, A; Wittig, B; Huhn, D (November 1999). "Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.". British Journal of Cancer 81 (6): 1009–16. doi:10.1038/sj.bjc.6690800. PMID 10576658.
  12. ↑ Märten, A; Ziske, C; Schöttker, B; Renoth, S; Weineck, S; Buttgereit, P; Schakowski, F; von Rücker, A; Sauerbruch, T; Schmidt-Wolf, IG (2000). "Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations.". Journal of immunotherapy (Hagerstown, Md. : 1997) 24 (6): 502–10. doi:10.1097/00002371-200111000-00007. PMID 11759073.
  13. ↑ Schmidt, J; Eisold, S; Büchler, MW; Märten, A (November 2004). "Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma.". Cancer immunology, immunotherapy : CII 53 (11): 1018–26. doi:10.1007/s00262-004-0554-4. PMID 15185013.
  14. ↑ Hombach, AA; Rappl, G; Abken, H (December 2013). "Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".". Molecular therapy : the journal of the American Society of Gene Therapy 21 (12): 2268–77. doi:10.1038/mt.2013.192. PMID 23985696.
  15. ↑ Tettamanti, Sarah; Marin, Virna; Pizzitola, Irene; Magnani, Chiara F.; Giordano Attianese, Greta M. P.; Cribioli, Elisabetta; Maltese, Francesca; Galimberti, Stefania; Lopez, Angel F.; Biondi, Andrea; Bonnet, Dominique; Biagi, Ettore (May 2013). "Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor". British Journal of Haematology 161 (3): 389–401. doi:10.1111/bjh.12282.
  16. ↑ Chan, JK; Hamilton, CA; Cheung, MK; Karimi, M; Baker, J; Gall, JM; Schulz, S; Thorne, SH; Teng, NN; Contag, CH; Lum, LG; Negrin, RS (15 March 2006). "Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.". Clinical cancer research : an official journal of the American Association for Cancer Research 12 (6): 1859–67. doi:10.1158/1078-0432.ccr-05-2019. PMID 16551871.
  17. ↑ Tita-Nwa, F; Moldenhauer, G; Herbst, M; Kleist, C; Ho, AD; Kornacker, M (December 2007). "Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.". Cancer immunology, immunotherapy : CII 56 (12): 1911–20. doi:10.1007/s00262-007-0333-0. PMID 17487487.

External links

See also

This article is issued from Wikipedia - version of the Thursday, May 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.